Not all antibodies are equal

le Booth, Laurence
Foilsithe 2013

Repurposing Tecfidera for cancer

le Booth, Laurence, Malkin, Mark, Dent, Paul
Foilsithe in Aging (Albany NY) (2016)

Not the comfy chair! Cancer drugs that act against multiple active sites

le Booth, Laurence, Poklepovic, Andrew, Dent, Paul
Foilsithe in Expert Opin Ther Targets (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

le Dent, Paul, Booth, Laurence, Poklepovic, Andrew
Foilsithe in Immunometabolism (2019)

HSPA5/Dna K May Be a Useful Target for Human Disease Therapies

le Booth, Laurence, Roberts, Jane L., Dent, Paul
Foilsithe in DNA Cell Biol (2015)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species

le Roberts, Jane L., Poklepovic, Andrew, Booth, Laurence
Foilsithe in Oncotarget (2017)

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

le Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Foilsithe in Cancer Biol Ther (2018)

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib

le Booth, Laurence A., Roberts, Jane L., Dent, Paul
Foilsithe in Semin Cancer Biol (2019)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

le Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Foilsithe in Oncotarget (2017)

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

le Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Foilsithe in Cancer Biol Ther (2017)

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody

le Booth, Laurence, Roberts, Jane Lisa, Poklepovic, Andrew, Dent, Paul
Foilsithe in Cancer Biol Ther (2018)

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells

le Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Foilsithe in Oncol Signal (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

le Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Foilsithe in Front Oncol (2019)

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

le Booth, Laurence, West, Cameron, Hoff, Daniel Von, Dent, Paul
Foilsithe in Front Oncol (2020)

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

le Booth, Laurence, West, Cameron, Von Hoff, Daniel, Dent, Paul
Foilsithe in Front Oncol (2021)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic

le Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Foilsithe in Front Oncol (2016)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

le Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Gordon, Sarah, Dent, Paul
Foilsithe in Oncotarget (2016)

HDAC inhibitors enhance the immunotherapy response of melanoma cells

le Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul
Foilsithe in Oncotarget (2017)

Valproate augments Niraparib killing of tumor cells

le Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Poklepovic, Andrew, Dent, Paul
Foilsithe in Cancer Biol Ther (2018)

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

le Booth, Laurence, Roberts, Jane L., Kirkwood, John, Poklepovic, Andrew, Dent, Paul
Foilsithe in Adv Cancer Res (2018)